Top shareholders of AMLX - Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Institutional Holders of Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) as of Q1 2022
As of 31 Mar 2022,
Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) was held by
72 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
23,420,880 shares.
The largest 10 holders included
VIKING GLOBAL INVESTORS LP, Bain Capital Life Sciences Investors, LLC, BOXER CAPITAL, LLC, PERCEPTIVE ADVISORS LLC, Rock Springs Capital Management LP, VANGUARD GROUP INC, Verition Fund Management LLC, TYBOURNE CAPITAL MANAGEMENT (HK) LTD, 683 Capital Management, LLC, and Alpha Wave Global, LP.
This page lists
72
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
Investor
Option
Weight %
Change %
Value $
* Price
Shares
Share Change
Activity
Report Period
Compare Q1 2022 vs Q4 2025 Across Filers
Q4 2025 holders
180
Q1 2022 holders
72
Holder diff
-108
Investor
Q4 2025 Shares
Q1 2022 Shares
Share Diff
Share Chg %
Q4 2025 Value $
Q1 2022 Value $
Value Diff $
Value Chg %
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance
the user experience and, if you allow them, measure engagement and deliver
advertising. Analytics and marketing storage stay off until you grant
consent. By clicking on "Agree and continue", you declare your consent to
the use of the selected optional cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.